Novartis
NEWS
Swiss pharma giant Novartis supported the company’s Series C financing round with a $75 million equity investment.
Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
Novartis will use a priority review voucher to expedite review of the treatment that could hit blockbuster status within two years of launching.
Alcon CEO says the company is “poised to achieve sustainable growth and create long-term shareholder value as a standalone company.”
Amgen is suing Novartis, alleging a breach of the partnership and seeking to terminate the 2015 contract. Novartis, in response, filed a lawsuit accusing Amgen of inappropriately attempting to end the alliance.
The Novartis subsidiary said it plans to offer jobs to the 150 employees currently working at the Colorado facility and add additional headcount there in the future.
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
JOBS
IN THE PRESS